Quality of Life of Cancer Patients under Adjuvant Mistletoe Treatment Results of a prospective, non-randomized, controlled, open study (post-marketing surveillance) with Iscador (R) M

被引:6
|
作者
Toelg, Michael [1 ]
Antonu, Herbert
Reiss, Bettina [1 ]
Ramos, Mac H. [2 ]
机构
[1] Mediveritas, Zweibruckenstr 15, DE-8033 Munich, Germany
[2] Weleda AG, CH-4144 Arlesheim, Switzerland
来源
关键词
prospective study; gynaecological cancer; mistletoe; chemotherapy; adverse events; quality of life; Iscador;
D O I
10.1159/000281947
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Mistletoe extracts (Viscum album L.) are applied in anthroposophic medicine in addition to conventional oncologic therapy, with the intention of reducing adverse events of chemotherapy and thereby improving the patients' qualitiy of life. Aim of the study: Documentation of the efficacy and tolerability of the anthroposophical mistletoe preparation Iscador (R) M in the treatment of patients with gynaecological cancer during chemotherapy, especially regarding the quality of life. Design: Prospective, controlled post-marketing surveillance. Methods: 36 female patients received a therapy with Iscador (R) in addition to the chemotherapeutical treatment, 37 female patients of the control group received exclusively a conventional therapy. The period of observation covered 6 months. Results: In comparison to the controlpatients the Iscador (R) patients showed better blood parameters and less physical and psychical impairment usually associated with chemotherapy. Conclusion: In summary, more patients of the Iscador (R) group experienced an amelioration or a stabilisation of their general condition and good tolerance of the mistletoe preparation.
引用
收藏
页码:294 / 299
页数:6
相关论文
共 46 条
  • [1] Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador)
    Grossarth-Maticek, R.
    Ziegler, R.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2008, 13 (03) : 107 - 120
  • [2] Oxcarbazepine in the treatment of epilepsy - An open-labelled, prospective, post-marketing surveillance study with oxcarbazepine in the treatment of 1385 patients with epilepsy
    Freidel, M.
    Krause, E.
    Kuhn, K.
    Peper, R.
    Vogel, H.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2007, 75 (02) : 100 - 106
  • [3] Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study
    Kab-Choong Kim
    Jeong-Hwan Yook
    Jürgen Eisenbraun
    Byung-Sik Kim
    Roman Huber
    BMC Complementary and Alternative Medicine, 12
  • [4] Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study
    Kim, Kab-Choong
    Yook, Jeong-Hwan
    Eisenbraun, Juergen
    Kim, Byung-Sik
    Huber, Roman
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 12
  • [5] CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study
    Ya A. Shliakhtunou
    Breast Cancer Research and Treatment, 2021, 186 : 439 - 451
  • [6] CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study
    Shliakhtunou, Ya A.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 439 - 451
  • [7] First interim results of Swiss post-marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing remitting multiple sclerosis (SWISSASCENT)
    Czaplinski, A.
    Jaquiery, E.
    Stellmes, P.
    Berger, C.
    Kurlandchikov, O.
    Lieder, F.
    Gass, S.
    Maier, T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 285 - 286
  • [8] Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study
    Gharibdoost, Farhad
    Salari, Amir-Hossein
    Salesi, Mansour
    Ebrahimi Chaharom, Faegheh
    Mottaghi, Peyman
    Hosseini, Mansour
    Sahebari, Maryam
    Nazarinia, Mohammadali
    Mirfeizi, Zahra
    Shakibi, Mohammadreza
    Moussavi, Hamidreza
    Karimifar, Mansour
    Mowla, Karim
    Karimzadeh, Hadi
    Anjidani, Nassim
    Jamshidi, Ahmadreza
    ADVANCES IN THERAPY, 2021, 38 (02) : 1290 - 1300
  • [9] Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study
    Farhad Gharibdoost
    Amir-Hossein Salari
    Mansour Salesi
    Faegheh Ebrahimi Chaharom
    Peyman Mottaghi
    Mansour Hosseini
    Maryam Sahebari
    Mohammadali Nazarinia
    Zahra Mirfeizi
    Mohammadreza Shakibi
    Hamidreza Moussavi
    Mansour Karimifar
    Karim Mowla
    Hadi Karimzadeh
    Nassim Anjidani
    Ahmadreza Jamshidi
    Advances in Therapy, 2021, 38 : 1290 - 1300
  • [10] Spiritual Care Therapy on Quality of Life in Cancer Patients and Their Caregivers: A Prospective Non-randomized Single-Cohort Study
    A. Sankhe
    K. Dalal
    V. Agarwal
    P. Sarve
    Journal of Religion and Health, 2017, 56 : 725 - 731